[1] Othman R Alharbi, Nahla A Azzam, Ahmed S Almalki, et al. Clinical epidemiology of ulcerative colitis in arabs based on the montréal classification[J]. World J Gastroenterol, 2014, 20(46): 17525-17531.
[2] Afshin Shafaghi, Fariborz Mansour-ghanaei, Maryam Rostamnejad, et al. Anti-cyclic citrullinated peptide antibodies in ulcerative colitis, and its relation with disease activity[J]. Med J Islam Repub Iran, 2014, 28(76):1-6.
[3] 国家药典委员会. 中华人民共和国药典[M]. 二部. 北京: 化学工业出版社, 2010: 附录181-182.
[4] Morris G P, Beck P L, Herridge M S, et al. Hapten-induced model of chronic inflammation and ulceration in the rat colon[J]. Gastroenterology, 1989, 96(3):795–803.
[5] Walter E Cromer, Chaitanya V Ganta, Mihir Patel, et al. VEGF-A isoform modulation in an preclinical TNBS model of ulcerative colitis: protective effects of a VEGF164b therapy[J]. J Translational Medicine, 2013, 11(11):207.
[6] Frank Heller, Ivan J Fuss, Edward E Nieuwenhuis, et al. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells [J] .Immunity, 2002, 17(5): 629-638.
[7] Lim Sung-Chu, Lee Tae-Beum, Choi Cheol-Hee, et al. Expression of cyclooxygenase-2 and its relationship to p53 accumulation in colorectal cancers[J]. J Yonsei Medical, 2007, 48(3): 495-501.
[8] 刘彤华主编. 诊断病理学图谱[M]. 第1版. 北京: 人民卫生出版社, 1998: 5.
[9] 郭庆红. 溃疡性结肠炎116例临床分析[D]. 长春: 吉林大学, 2004.
[10] 郭海荣. 甘草酸二铵对溃疡性结肠炎大鼠作用的实验研究[D]. 太原: 山西医科大学, 2009.
[11] Abraham C, Cho J H. Inflammatory bowel disease [J]. N Engl J Med, 2009, 361(21): 2066-2078.
[12] 杨锐. 伊索拉定灌肠治疗溃疡性结肠炎的临床疗效观察[D],长春:吉林大学, 2012.
[13] Tozawa K, Hanai H, Sugimoto K, et al. Evidence for the critical role of interleukin‐12 but not interferon‐γ in the pathogenesis of experimental colitis in mice[J]. J Gastroenterology Hepatology, 2003, 18(5): 578-587.
[14] 杨丽. 正交设计对“加味通腑汤”进行组方优化的实验 (活血化瘀组)[D]. 沈阳: 辽宁中医药大学, 2012,9-14.
[15] 毛颖, 王秀珍, 张喆, 等. 溃疡性结肠炎动物模型研究进展[J]. 中医药信息, 2013, (4): 126-130.
[16] 罗凤燕, 白爱平. 溃疡性结肠炎动物模型的研究进展[J]. 世界华人消化杂志, 2013, 21(7): 607-613.
[17] 邓莉, 胡晋红. 化学诱导型结肠炎动物模型的研究进展[J]. 中国药理学通报, 2005, 21(5): 522-526.
[18] Arie Levine, Gabriel Kenet, Rafael Bruck, et al. Effect of heparin on tissue binding activity of fibroblast growth factor and heparin-binding epidermal growth factor in experimental colitis in rats[J]. Pediatric Research, 2002, 51(5): 635-640.
[19] Kimura I, Naghama S, Kawasaki M, et al. Study on the experimental ulcerative colitis model induced by sulfate sodium (DSS) in rat[J]. Nippon Yakurigaku Zasshi. 1996, 108(5): 259-266.
[20] 李晨. 大蒜素对炎症性肠病的治疗作用及其对 MAPK 信号通路的影响[D].广州: 南方医科大学, 2012.
[21] Guan Qing-dong, Ma Yan-bing, China-Li Hillman, et al. Targeting IL-12/IL-23 by employing a p40 peptide-based vaccine ameliorates TNBS-induced acute and chronic murine colitis[J]. Molecular Medicine, 2011, 17(7-8): 646.
[22] Stefano Fiorucci, Andrea Mencarelli, Barbara Palazzetti, et al. Importance of innate immunity and collagen binding integrin α1β1 in TNBS-induced colitis[J]. Immunity, 2002, 17(6): 769-780.
[23] 赵晶. 杨梅素对 DSS 诱导的小鼠急性溃疡性结肠炎的保护作用研究[D]. 长春: 吉林大学, 2013.
[24] Monica Boirivant, Ivan J Fuss, Alan Chu, et al. Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4[J]. J Exp Med, 1998, 188(10): 1929-1939.
[25] 王倩, 田慧, 张力. 诱发溃疡性结肠炎动物模型化学方法及评价[J]. 神经药理学报, 2013, 3(4):38-43.
[26] 庞艳华, 郑长青. Thl/Th2细胞亚群与炎症性肠病的关系[J].世界华人消化杂志, 2004, 12(8): 1922-1924.
[27] Jussila A, Virta L J, Kautiainen H, et al. Increasing incidence of inflammatory bowel diseases between 2000 and 2007: a nationwide register study in Finland[J]. Inflamm Bowel Dis, 2012, 18(3): 555-561.
[28] Guillaume Bouguen, Jean-Baptiste Chevaux, Laurent Peyrin-Biroulet. Recent advances in cytokines: therapeutic implications for inflammatory bowel diseases [J]. World J Gastroenterol, 2011, 17(5): 547-556.
[29] Franco Scaldaferri, Claudio Fiocchi. Inflammatory bowel disease: progress and current concepts of etiopathogenesis [J]. J Dig Dis, 2007, 8(4): 171-178.
[30] Dignass A, Van Assche G, Lindsay J O, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management[J]. J CrohnsColitis, 2010, 4(1):28-62.
[31] Kornbluth A, Sachar D B. Ulcerative colitis practice guidelines in adults: American college of gastroenterology, practice parameters committee[J]. Am J Gastroenterol, 2010, 105(3) : 501-523.
[32] Daniel C Baumgart, William J Sandborn. Crohn’s disease[J]. Lancet, 2012, 380(9853):1590-1605.
[33] Danese S, Fiocchi C. Ulcerative colitis[J]. N Engl J Med, 2011, 365(18): 1713-1725.
[34] 郑汉臣. 药用植物学[M].北京:人民卫生出版社, 2010: 166. |